Autologous T-cell vaccination for multiple sclerosis: A perspective on progress

Arthur Vandenbark, Rivka Abulafia-Lapid

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.

Original languageEnglish (US)
Pages (from-to)265-273
Number of pages9
JournalBioDrugs
Volume22
Issue number4
DOIs
StatePublished - 2008

Fingerprint

Multiple Sclerosis
Vaccination
T-Lymphocytes
Myelin Sheath
Immunity
Autoimmune Diseases
Longitudinal Studies
Vaccines
Tissue Donors
Recurrence

Keywords

  • Immunomodulators, therapeutic use
  • Multiple sclerosis, treatment
  • Vaccines, therapeutic use

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Autologous T-cell vaccination for multiple sclerosis : A perspective on progress. / Vandenbark, Arthur; Abulafia-Lapid, Rivka.

In: BioDrugs, Vol. 22, No. 4, 2008, p. 265-273.

Research output: Contribution to journalArticle

Vandenbark, Arthur ; Abulafia-Lapid, Rivka. / Autologous T-cell vaccination for multiple sclerosis : A perspective on progress. In: BioDrugs. 2008 ; Vol. 22, No. 4. pp. 265-273.
@article{ae87993a5fa249bd929cee23406fae5e,
title = "Autologous T-cell vaccination for multiple sclerosis: A perspective on progress",
abstract = "T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.",
keywords = "Immunomodulators, therapeutic use, Multiple sclerosis, treatment, Vaccines, therapeutic use",
author = "Arthur Vandenbark and Rivka Abulafia-Lapid",
year = "2008",
doi = "10.2165/00063030-200822040-00006",
language = "English (US)",
volume = "22",
pages = "265--273",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Autologous T-cell vaccination for multiple sclerosis

T2 - A perspective on progress

AU - Vandenbark, Arthur

AU - Abulafia-Lapid, Rivka

PY - 2008

Y1 - 2008

N2 - T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.

AB - T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of the disease-causing agent - in this case, myelin-reactive T cells - that have been selected and expanded from each MS donor and then re-injected after irradiation to induce protective immunity. This anti-T-cell immunity consistently results in selective deletion or regulation of the targeted pathogenic T cells in vivo. Longitudinal studies have established that TCV is safe and often results in a reduced relapse rate and clinical stability or improvement, at least temporarily, in the majority of treated MS patients. These results lend direct support to the involvement of inflammatory myelin-reactive T cells in the MS disease process. However, these hopeful trends reported in a number of pilot trials await validation in larger proof-of-principle trials that are now in progress.

KW - Immunomodulators, therapeutic use

KW - Multiple sclerosis, treatment

KW - Vaccines, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=47049096574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47049096574&partnerID=8YFLogxK

U2 - 10.2165/00063030-200822040-00006

DO - 10.2165/00063030-200822040-00006

M3 - Article

C2 - 18611069

AN - SCOPUS:47049096574

VL - 22

SP - 265

EP - 273

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 4

ER -